drugset / Trial / NCT06375707
Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
Phase 2
Unknown
144 enrolled
The First Affiliated Hospital with Nanjing Medical University
Zhejiang Cancer Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the efficacy and safety of Ribociclib in combination with NSAI versus physician's choice of chemotherapy sequential endocrine therapy in HR+/HER2- advanced breast cancer.
Timeline
- Start
- 2024-01-09
- Primary completion
- 2025-11
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | 1 mg | Oral |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Docetaxel | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Ribociclib | Small molecule | 600 mg | Oral |
| Subject | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |